This cohort study assesses the frequency of approval and marketing of skinny-label biosimilars and their savings to Medicare.
No takes yet. Share an insight, caveat, or question.
Egilman et al. (2022) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: